Last reviewed · How we verify
lubiprostone (Amitiza)
Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel movements.
Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel movements. Used for Chronic idiopathic constipation, Irritable bowel syndrome with constipation (IBS-C), Opioid-induced constipation.
At a glance
| Generic name | lubiprostone (Amitiza) |
|---|---|
| Also known as | Amitiza |
| Sponsor | Henry Ford Health System |
| Drug class | ClC-2 chloride channel activator |
| Target | ClC-2 chloride channel |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Lubiprostone is a prostaglandin F analog that selectively activates ClC-2 chloride channels on the apical membrane of gastrointestinal epithelial cells. This activation increases chloride and fluid secretion into the intestinal lumen, which increases stool frequency and softens stool consistency. The mechanism does not depend on neural or hormonal pathways, making it effective across various types of constipation.
Approved indications
- Chronic idiopathic constipation
- Irritable bowel syndrome with constipation (IBS-C)
- Opioid-induced constipation
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- Headache
- Vomiting
Key clinical trials
- Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer (PHASE2)
- Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation (PHASE3)
- The Effect of Adding Lubiprostone to Standard Large-Volume PEG-ELS on The Quality of Inpatient Colonoscopy Preparation
- Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- Anorectal Manometery in Pediatric Chronic Refractory Constipation (PHASE1, PHASE2)
- Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease (PHASE3)
- Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy (PHASE2)
- Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lubiprostone (Amitiza) CI brief — competitive landscape report
- lubiprostone (Amitiza) updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI